 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Cambridge Antibody Technology Group plc
 |
Cambridge Antibody Technology Group plc |
 |
 |
 |
PROFILE |
 |
Cambridge Antibody Technology (CAT) uses cloned human antibodies to discover and develop pharmaceuticals. Utilizing proprietary genomics and proteomics technologies, the company analyzes and identifies gene sequences and the proteins they contain. Once a protein is isolated, it is bombarded with bacterial viruses (phages). CAT then engineers human antibodies based on which phages bind with the protein. The company has drugs in clinical trials to treat rheumatoid arthritis, autoimmune and inflammatory disorders, fibrotic conditions, and scarring following glaucoma surgery. It has drug development deals with such firms as AstraZeneca, BASF Pharma, Human Genome Sciences, and Pfizer.
COMPETITION |
 |
Ciphergen Biosystems, Inc. (CIPH)
Medarex, Inc. (MEDX)
Oxford GlycoSciences Plc (OGS)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: September
2000 Sales (mil.): 14.80
1-Yr. Sales Growth: 401.3%
Employees: 161
Revenue per employee: $91,925.47
KEY PEOPLE |
 |
David Chiswell
CEO
John Aston
CFO
CONTACT INFO |
 |
The Science Park
Melbourn Cambridgeshire SG8 6JJ, United Kingdom
Phone: 44-1763-263-233
Fax: 44-1763-263-413
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |